Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07395232 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
A Phase 3 study of Atopic Keratoconjunctivitis, sponsored by Dompé Farmaceutici S.p.A.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 19
- Study locations
NCT07395232 is a Phase 3 study of Atopic Keratoconjunctivitis that is actively recruiting participants, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 138 participants. The trial reports 19 study locations across 8 states.
The verdict
NCT07395232, a Phase 3 study of Atopic Keratoconjunctivitis, is actively recruiting participants, sponsored by Dompé Farmaceutici S.p.A.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG DFL24498
- DRUG dexamethasone sodium phosphate (DSP) ophthalmic solution
Study Locations (19)
Other
- IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia - Bologna
- Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti - Chieti
- Azienda Ospedaliero Universitaria Careggi - Florence
- Fondazione Policlinico Universitario Campus Bio-Medico - Roma
- AOU Policlinico Umberto I - Roma
- Azienda Ospedaliera Universitaria Integrata Verona - Verona
- METAVISION ARRUZAFA S.L. (Hospital Arruzafa) - Córdoba
- Miranza Galicia - Santiago de Compostela
- Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM) - Valencia
- OBA - Universidad de Valladolid - Valladolid
- Hospital Universitario Miguel Servet - Zaragoza
Florida
- Bowden Eye Associates - Southside Location - Jacksonville
- University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute - Miami
Georgia
- Clayton Eye Clinical Research - Morrow
Missouri
- Ophthalmology Associates - St Louis
New York
- NYU Langone Health - Eye Center - New York
North Carolina
- Duke Eye Center - Ophthalmology - Durham
Tennessee
- Total Eye Care, PA - Memphis
Texas
- Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07395232
The ClinicalTrials.gov registry entry for NCT07395232 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Keratoconjunctivitis appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT07395232 reports 19 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07395232 about?
NCT07395232 is a clinical study titled "An Efficacy and Safety Study of DFL24498 in the Treatment of AKC". This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled i...
What is the current status of trial NCT07395232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2025-12-01. Estimated completion is 2027-05.
What conditions does trial NCT07395232 study?
This clinical trial studies the following conditions: Atopic Keratoconjunctivitis.
What interventions are being tested in trial NCT07395232?
The interventions under investigation include: Vehicle (DRUG), DFL24498 (DRUG), dexamethasone sodium phosphate (DSP) ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07395232?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07395232 being conducted?
This trial has 19 study locations across Florida, Georgia, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.